RESUMO
Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in GLA. It manifests in hemizygous males and in many heterozygous females. Cardiovascular and renal involvement are frequent. Adiponectin is a circulating hormone that has been linked to numerous disease conditions including heart and kidney failure. In the present pilot study, we investigated plasma adiponectin levels in a cohort of 56 individuals with a genetic diagnosis of Fabry disease. Adiponectin levels did not differ between patients and controls. However, in male patients, significantly decreased adiponectin levels were associated with cardiovascular manifestation, while increased levels were associated with renal involvement. Similar trends in female patients did not reach statistical significance. Lyso-Gb3, a metabolite with good diagnostic/screening performance, was not indicative of organ involvement. In combination, adiponectin and Lyso-Gb3 may be of value for identification and stratification of Fabry patients. A potential additional relevance for prognosis and monitoring should be addressed by future studies in larger cohorts.
Assuntos
Adiponectina/sangue , Biomarcadores , Doença de Fabry/sangue , Doença de Fabry/diagnóstico , Fenótipo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Rim/metabolismo , Rim/patologia , Masculino , Pessoa de Meia-Idade , Especificidade de Órgãos , Fatores Sexuais , Avaliação de Sintomas , Adulto JovemRESUMO
Gaucher disease (GD) is a lysosomal storage disorder that responds well to enzyme replacement therapy (ERT). Certain laboratory parameters, including blood concentration of glucosylsphingosine (Lyso-Gb1), the lyso-derivate of the common glycolipid glucocerebroside, correlate with clinical improvement and are therefore considered candidate-monitoring biomarkers. Whether they can indicate a reduction or loss of treatment efficiency, however, has not been systematically addressed for obvious reasons. We established and validated measurement of Lyso-Gb1 from dried blood spots (DBSs) by mass spectrometry. We then characterized the assay's longitudinal performance in 19 stably ERT-treated GD patients by dense monitoring over a 3-year period. The observed level of fluctuation was accounted for in the subsequent development of a unifying data normalization concept. The resulting approach was eventually applied to data from Lyso-Gb1 measurements after an involuntary treatment break for all 19 patients. It enabled separation of the "under treatment" versus "not under treatment" conditions with high sensitivity and specificity. We conclude that Lyso-Gb1 determination from DBSs indicates treatment issues already at an early stage before clinical consequences arise. In addition to its previously shown diagnostic utility, Lyso-Gb1 thereby qualifies as a monitoring biomarker in GD patients.
Assuntos
Biomarcadores/sangue , Teste em Amostras de Sangue Seco/métodos , Terapia de Reposição de Enzimas/métodos , Doença de Gaucher/patologia , Glucosilceramidase/administração & dosagem , Psicosina/análogos & derivados , Adolescente , Adulto , Idoso , Criança , Estudos de Coortes , Feminino , Seguimentos , Doença de Gaucher/sangue , Doença de Gaucher/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Psicosina/sangue , Adulto JovemRESUMO
The role of glucosylsphingosine (lyso-Gb1), a downstream metabolic product of glucosylceramide, for monitoring treated and untreated children with Gaucher disease (GD) has not yet been studied. We reviewed the clinical charts of 81 children (<18 years), 35 with mild type 1 GD (GD1), 34 with severe GD1 and 12 with type 3 GD (GD3), followed at Shaare Zedek Medical Center between 2014-2018. Disease severity for GD1 was based on genotypes. Forty children (87%) with severe GD1 and GD3 received enzyme replacement therapy (ERT) compared to two children (6%) with mild GD1. Lyso-Gb1 measurements were conducted on dried blood spot samples taken at each clinic visit. Lyso-Gb1 levels were significantly lower in children with mild compared to severe GD1 (p = 0.009). In untreated children, lyso-Gb1 levels were inversely correlated with platelet counts. During follow-up, lyso-Gb1 increased in almost 50% of untreated children, more commonly in younger children. In treated children, lyso-Gb1 levels were inversely correlated with hemoglobin levels. The increase of lyso-Gb1 while receiving ERT, seen in eight children, was partly associated with compliance and weight gain. Lyso-Gb1 seems to be a useful biomarker for monitoring children with GD and should be included in the routine follow-up. Progressive increase in lyso-Gb1 levels in untreated children suggests ERT initiation.
Assuntos
Doença de Gaucher/sangue , Psicosina/análogos & derivados , Adolescente , Biomarcadores/sangue , Criança , Pré-Escolar , Terapia de Reposição de Enzimas , Feminino , Doença de Gaucher/diagnóstico , Doença de Gaucher/tratamento farmacológico , Glucosilceramidase/uso terapêutico , Humanos , Lactente , Masculino , Psicosina/sangueRESUMO
Two-photon microscopy (TPM) allows high contrast imaging at a subcellular resolution scale. In this work, the microscopy technique was applied to visualize corneal structures in two mouse models (BALB/c and B6.Cg-Tg(Thy1-YFP)16Jrs/J) in vivo. In particular, the transgenic Thy1-YFP mice expressing the yellow fluorescent protein (YFP) in all motor and sensory neurons had been used for investigating the nerve fiber density in healthy and streptozotocin-diabetic mice. This model is clinically relevant since patients suffering from diabetes mellitus have a high risk to develop small fiber neuropathy. Nonlinear laser scanning microscopy displayed a reduction of nerve fiber density in streptozotocin-diabetic versus healthy mice and confirmed data obtained by confocal laser scanning microscopy (CLSM). In recent years, corneal CLSM was proved to be an appropriate non-invasive tool for an early diagnosis of diabetic neuropathy. Nevertheless, validation of the CLSM method for the clinical routine is currently a matter of investigation and requires confirmation by further studies and complementary techniques. Thus, the present study provides further evidence of corneal confocal microscopy as a promising technique for non-invasive detection of diabetic neuropathy. Information derived from these experiments may become clinically relevant and help to develop new drugs for treatment of diabetic neuropathy.
Assuntos
Córnea/patologia , Diabetes Mellitus Experimental , Retinopatia Diabética/diagnóstico , Microscopia Confocal/métodos , Microscopia de Fluorescência/métodos , Animais , Retinopatia Diabética/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Transgênicos , Reprodutibilidade dos TestesRESUMO
Niemann-Pick type C1 (NPC1) disease is a lysosomal storage disease characterized by a deficiency of NPC1 gene function. The malfunction of protein results in a progressive accumulation of lipids in many organs. A combined approach with substrate-reduction therapy (SRT) and byproduct therapy (BPT) has been shown to ameliorate the disease course in a mutant mouse model (NPC1(-/-)). The present study examines the morphological parameters underlying these changes. For the combined SRT/BPT treatment, NPC1(-/-) mutant mice (NPC1(-/-SRT/BPT)) were injected with allopregnanolone/cyclodextrin weekly, starting at postnatal day (P) 7. Starting at P10, a miglustat injection was administered daily until P23. Thereafter, miglustat was added to the powdered chow. For the sham treatment, both mutant NPC1(-/-) (NPC1(-/-sham)) and wild-type (NPC1(+/+sham)) mice received an NaCl injection and were fed powdered chow without miglustat. Analysis was performed on cerebellar slices by histology and immunohistochemistry. The volumes and cell counts of cerebellar structures were quantified. Additionally, ultrastructural analysis was performed with transmission electron microscopy. In agreement with previous studies, the current study demonstrates Purkinje cell degeneration in the mutant mice, which was partially abrogated by SRT/BPT. The volumes of cerebellar white matter and molecular layer were reduced as well. Also, the number of neurons was reduced in granular and molecular layers. However, only the molecular layer benefited from the therapy, as shown by an increase in the volume and the amount of neurons. The volume and number of neurons of the deep cerebellar nuclei were significantly decreased in mutant mice; an appreciable therapeutic benefit could be demonstrated for the nucleus interpositus.
Assuntos
1-Desoxinojirimicina/análogos & derivados , Cerebelo/efeitos dos fármacos , Ciclodextrinas/uso terapêutico , Degeneração Neural/tratamento farmacológico , Doença de Niemann-Pick Tipo C/tratamento farmacológico , Pregnanolona/uso terapêutico , 1-Desoxinojirimicina/farmacologia , 1-Desoxinojirimicina/uso terapêutico , Animais , Contagem de Células , Cerebelo/patologia , Ciclodextrinas/farmacologia , Modelos Animais de Doenças , Progressão da Doença , Quimioterapia Combinada , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/uso terapêutico , Camundongos , Degeneração Neural/patologia , Neurônios/efeitos dos fármacos , Neurônios/patologia , Doença de Niemann-Pick Tipo C/patologia , Pregnanolona/farmacologiaRESUMO
BACKGROUND: Niemann-Pick type C1 (NPC1) disease is an inherited lysosomal storage disease caused by mutation of the Npc1 gene, resulting in a progressive accumulation of unesterified cholesterol and glycolipids in lysosomes of multiple tissues and leading to neurodegeneration and other disease. In Npc1 mutant mice, retinal degeneration including impaired visual function, lipofuscin accumulation in the pigment epithelium and ganglion cells as well as photoreceptor defects has been found. However, the pathologies of other individual cell types of the retina in Npc1 mutant mice are still not fully clear. We hypothesized that horizontal cells, amacrine cells, bipolar cells and glial cells are also affected in the retina of Npc1 mutant mice. RESULTS: Immunohistochemistry and electron microscopy were used to investigate pathologies of ganglion cells, horizontal cells, amacrine cells, bipolar cells, and optic nerves as well as altered activity of glial cells in Npc1 mutant mice. Electron microscopy reveals that electron-dense inclusions are generally accumulated in ganglion cells, bipolar cells, Müller cells, and in the optic nerve. Furthermore, abnormal arborisation and ectopic processes of horizontal and amacrine cells as well as defective bipolar cells are observed by immunohistochemistry for specific cellular markers. Furthermore, hyperactivity of glial cells, including astrocytes, microglial cells, and Müller cells, is also revealed. CONCLUSIONS: Our data extend previous findings to show multiple defects in the retina of Npc1 mutant mice, suggesting an important role of Npc1 protein in the normal function of the retina.
Assuntos
Neuroglia/patologia , Neurônios/patologia , Doença de Niemann-Pick Tipo C/patologia , Retina/patologia , Animais , Apoptose , Modelos Animais de Doenças , Imuno-Histoquímica , Peptídeos e Proteínas de Sinalização Intracelular , Camundongos Knockout , Microscopia Eletrônica , Neuroglia/metabolismo , Neurônios/metabolismo , Proteína C1 de Niemann-Pick , Doença de Niemann-Pick Tipo C/metabolismo , Nervo Óptico/metabolismo , Nervo Óptico/patologia , Proteínas/genética , Proteínas/metabolismo , Retina/metabolismoRESUMO
The aim of this study was to examine the murine subbasal nerve fibre plexus (SNP) regeneration altered by surgical dissection. Investigations in the mouse model addressed the regeneration capabilities of the SNP, and the influence of local ciliary neurotrophic factor (CNTF) application on the regeneration process. In preliminary experiments, the healthy mouse cornea was monitored using in vivo confocal laser-scanning microscopy (CLSM) from the age of 8-52 weeks, to reveal and rule out the age-dependent changes in SNP. Nerve fibre density (NFD) was determined with the semi-automatic nerve tracing program NeuronJ. No quantitative or qualitative changes in NFD were detected in untreated animals over time; mean NFD in mice aged 8 weeks (28.30 ± 9.12 mm/mm2), 16 weeks (29.23 ± 7.28 mm/mm2), 30 weeks (26.31 ± 8.58 mm/mm2) and 52 weeks (26.34 ± 6.04 mm/mm2) showed no statistically significant differences between time points (p > 0.05). For regeneration studies a circular incision through corneal epithelium and anterior stroma of minimum 60 µm depth was generated with a custom-made guided trephine system to cut the subbasal corneal nerves in adult mice. The corneal nerve pattern was monitored and NFD was measured before and up to 8 weeks after surgery. Animals were divided in three groups each comprising 6 mice. The CNTF group received eye drops containing CNTF (25 ng/ml) 3 times daily for 3 weeks, whereas the control group received no further medication. In the sham group the same treatment schedule was applied as in CNTF group, using vehicle. The regenerating subbasal nerve fibres sprouted out of stromal nerves within the cut and additionally regrew over the scar rim from outside. They showed parallel orientation but were thinner than before incision. Whorl patterning was observed after 4 weeks. All three groups revealed a marked NFD reduction starting at one week after incision, followed by continuous recovery. After 8 weeks the NFD reached 23.5 ± 2.4 mm/mm2 (78% of baseline), 21.9 ± 1.6 mm/mm2 (73% of baseline) and 29.2 ± 3.4 mm/mm2 (93% of baseline) in the control, sham and CNTF group, respectively. By comparison with control and sham group, the CNTF group demonstrated significantly higher NFD at every observation time point. The mouse cornea provides a practicable animal model for in vivo CLSM monitoring of corneal nerve behaviour over time and following injury. Non-penetrating trephination generated a severe reduction in the NFD of the SNP, but murine corneas recovered to pre-injury NFD levels within 8 weeks. Local application of CNTF served merely to temporarily accelerate the recovery of NFD.
Assuntos
Fator Neurotrófico Ciliar/farmacologia , Córnea/inervação , Fibras Nervosas/fisiologia , Regeneração Nervosa/efeitos dos fármacos , Nervo Oftálmico/fisiologia , Animais , Fator Neurotrófico Ciliar/administração & dosagem , Lesões da Córnea , Modelos Animais de Doenças , Ferimentos Oculares Penetrantes/fisiopatologia , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Microscopia Confocal , Soluções Oftálmicas , Cicatrização/fisiologiaRESUMO
The high degree of clinical routine in percutaneous transluminal coronary angioplasty (PTCA) with and without stenting has not changed the fact that a large number of coronary heart disease patients are still affected by post-operative complications such as restenosis and thrombosis. Because re-endothelialization is the crucial aspect of wound healing after cardiovascular implant surgery, there is a need for modern biomaterials to aid endothelial cells in their adhesion and functional recovery post-stenting. This study systematically examines the potential of numerous chemical polymer modifications with regard to endothelialization. Poly(ε-caprolactone) (PCL) and its chemically activated forms are investigated in detail, as well as the impact of polymer surface morphology and precoating with matrix protein. Human umbilical vein endothelial cells (HUVECs) are used to characterize endothelial cell responses in terms of in vitro viability and adhesion. As a potential component in drug eluting implants, VEGF is applied as stimulus to boost endothelial cell proliferation on the polymer. In conclusion, plasma chemical activation of PCL combined with VEGF stimulation best enhances in vitro endothelialization. Examining the impact of morphological, chemical and biological modifications of PCL, this study makes an important new contribution towards the existing body of work on polymer endothelialization.
Assuntos
Endotélio Vascular/efeitos dos fármacos , Poliésteres/química , Fator A de Crescimento do Endotélio Vascular/farmacologia , Materiais Biocompatíveis , Endotélio Vascular/citologia , Células Endoteliais da Veia Umbilical Humana , Humanos , Microscopia Eletrônica , Propriedades de SuperfícieRESUMO
PURPOSE: Keratoconus is a predominantly bilateral form of corneal degeneration that is associated with central thinning and cone-shaped bulging of the cornea usually accompanied by a progressive reduction in visual acuity. A recent therapeutic option is cross-linking, a procedure designed to prevent the progression of keratoconus by the photochemical cross-linkage of collagen fibers. PATIENTS AND METHODS: Eight eyes in 8 patients with progressive keratoconus were treated by the photochemical cross-linking method using riboflavin and UVA light. In addition to the usual ophthalmological examinations, patients were examined pre- and postoperatively by confocal in vivo laser scanning microscopy. Follow-up examinations were performed at 2 weeks and at 2, 4, 6 and 12 months postoperatively. RESULTS: Complete regeneration of corneal epithelium was detected by 2 weeks after therapy at the latest. The sub-basal nerve plexus could not be visualized by confocal microscopy after treatment. Immediately after treatment, the anterior corneal stroma had a honeycombed appearance but without the typical hyperreflective keratocyte nuclei. At about 6 months postoperatively, the corneal stroma had virtually regained its normal configuration. After therapy, confocal microscopy revealed that corneal endothelium was normal in terms of cell density and morphology at every time point. CONCLUSIONS: Confocal in vivo laser scanning microscopy is an investigative technique that permits reproducible visualization of structural changes in the cornea (epithelium, stroma and endothelium) following collagen cross-linking with riboflavin and UVA light. Once epithelial healing is complete, the epithelium and endothelium appear to be unaffected by the treatment. The most noteworthy structural changes, which are detected on confocal microscopy shortly after treatment, involve the anterior and middle corneal stroma. Over the course of time, up to 12 months postoperatively, these changes show a definite tendency to regress.
Assuntos
Colágeno/metabolismo , Substância Própria/patologia , Reagentes de Ligações Cruzadas/uso terapêutico , Ceratocone/patologia , Microscopia Confocal , Riboflavina/uso terapêutico , Raios Ultravioleta , Adulto , Contagem de Células , Substância Própria/metabolismo , Progressão da Doença , Endotélio Corneano/patologia , Feminino , Humanos , Ceratocone/tratamento farmacológico , Ceratocone/metabolismo , Masculino , Fotoquimioterapia , Fármacos Fotossensibilizantes/uso terapêutico , Resultado do TratamentoRESUMO
We implemented a collaborative diagnostic program in Lahore (Pakistan) aiming to establish the genetic diagnosis, and to asses diagnostic yield and clinical impact in patients with suspected genetic diseases. Local physicians ascertained pediatric patients who had no previous access to genetic testing. More than 1586 genetic tests were performed in 1019 individuals (349 index cases, 670 relatives). Most frequently performed tests were exome/genome sequencing (ES/GS, 284/78 index cases) and specific gene panels (55 index cases). In 61.3% of the patients (n = 214) a genetic diagnosis was established based on pathogenic and likely pathogenic variants. Diagnostic yield was higher in consanguineous families (60.1 vs. 39.5%). In 27 patients, genetic diagnosis relied on additional biochemical testing, allowing rapid assessment of the functional effect of the variants. Remarkably, the genetic diagnosis had a direct impact on clinical management. Most relevant consequences were therapy related such as initiation of the appropriated treatment in a timely manner in 51.9% of the patients (n = 111). Finally, we report 12 candidate genes among 66 cases with no genetic diagnosis. Importantly, three of these genes were validated as 'diagnostic' genes given the strong evidence supporting causality derived from our data repository (CAP2-dilated cardiomyopathy, ITFG2-intellectual disability and USP53-liver cholestasis). The high diagnostic yield, clinical impact, and research findings demonstrate the utility of genomic testing, especially when used as first-line genetic test. For patients with suspected genetic diseases from resource-limited regions, ES can be considered as the test of choice to achieve genetic diagnosis.
RESUMO
The introduction of disease-specific therapy for patients with type I Gaucher disease (GD1) was a revolution in the management of patients, but not without cost. Thus, the management of mildly affected patients is still debated. We herein report a long-term follow-up (median (range) of 20 (5-58) years) of 103 GD1 patients who have never received enzymatic or substrate reduction therapy. The median (range) platelet count and hemoglobin levels in last assessment of all but six patients who refused therapy (although recommended and approved) were 152 (56-408) × 103/mL and 13.1 (7.6-16.8) g/dL, respectively. Most patients had mild hepatosplenomegaly. Nine patients were splenectomized. No patient developed clinical bone disease. The median (range) lyso-Gb1 levels at last visit was 108.5 (8.1-711) ng/mL; lowest for patients with R496H/other and highest for patients refusing therapy. This rather large cohort with long follow-up confirms that mildly affected patients may remain stable for many years without GD-specific therapy. The challenge for the future, when newborn screening may detect all patients, is to be able to predict which of the early diagnosed patients is at risk for disease-related complications and therefore for early treatment, and who may remain asymptomatic or minimally affected with no need for disease-specific therapy.
RESUMO
BACKGROUND: Hyaline fibromatosis syndrome (HFS) is a rare clinical condition in which bi-allelic variants in ANTXR2 are associated with extracellular hyaline deposits. It manifests as multiple skin nodules, patchy hyperpigmentation, joint contractures and severe pain with movement. HFS shows some clinical overlap to Farber disease (FD), a recessive lysosomal storage disorder. RESULTS: We here present the largest cohort of independent, genetically confirmed HFS cases reported to date: in 19 unrelated index patients, we identified ten distinct homozygous ANTXR2 mutations, three of which are novel frame-shift variants. The associated clinical data are consistent with the previous hypothesis of non-truncating variants in the terminal exons 13-17 to confer rather mild phenotypes. The novel observation of gender-dependent disease manifestation in our cohort received support from a meta-analysis of all previously published cases. Untargeted blood-based metabolomics revealed patient samples to be biochemically distinct from control samples. Numerous potential HFS biomarker metabolites could thus be identified. We also found metabolomics profiles of HFS patients to highly overlap with those from FD patients. CONCLUSIONS: Our study extends the mutational spectrum for HFS, suggests gender-dependency of manifestation, and provides pilot metabolomics data for biomarker identification and a better pathomechanistic understanding of the disorder.
Assuntos
Síndrome da Fibromatose Hialina/genética , Adolescente , Adulto , Biomarcadores/metabolismo , Criança , Pré-Escolar , Estudos de Coortes , Lipogranulomatose de Farber/genética , Feminino , Estudos de Associação Genética , Humanos , Lactente , Masculino , Mutação/genética , Receptores de Peptídeos/genética , Adulto JovemRESUMO
Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. The diagnostic aspects of FD are poorly developed due to the rarity of the disease. In the present study, the screening for ceramides and related molecules was performed in Farber affected patients (n = 10), carriers (n = 11) and control individuals (n = 192). This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings.
Assuntos
Biomarcadores/análise , Portador Sadio/diagnóstico , Ceramidas/análise , Lipogranulomatose de Farber/diagnóstico , Ceramidase Ácida/genética , Adulto , Pré-Escolar , Cromatografia Líquida , Teste em Amostras de Sangue Seco , Lipogranulomatose de Farber/genética , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Mutação , Adulto JovemRESUMO
In glaucoma surgery, fibrotic processes occur, leading to impairment of liquid outflow. Activated fibroblasts are responsible for postoperative scarring. The transforming growth factor-ß (TGF-ß) pathway plays a key role in fibroblast function, differentiation and proliferation. The aim of this study was the characterization of the fibrotic potential of two subtypes of primary human ocular fibroblasts and the attempt to inhibit fibrotic processes specifically, without impairing cell viability. For fibrosis inhibition we focused on the small molecule pirfenidone, which has been shown to prevent pulmonary fibrosis by the decrease of the expression of TGF-ß1, TGF-ß2 and TGF-ß3 cytokines. For in vitro examinations, isolated human primary fibroblasts from Tenon capsule and human intraconal orbital fat tissues were used. These fibroblast subpopulations were analyzed in terms of the expression of matrix components responsible for postoperative scarring. We concentrated on the expression of collagen I, III, VI and fibronectin. Additionally, we analyzed the expression of α-smooth muscle actin, which serves as a marker for fibrosis and indicates transformation of fibroblasts into myofibroblasts. Gene expression was analyzed by rtPCR and synthesized proteins were examined by immunofluorescence and Western blot methods. Proliferation of fibroblasts under different culture conditions was assessed using BrdU assay. TGF-ß1 induced a significant increase of cell proliferation in both cell types. Also the expression of some fibrotic markers was elevated. In contrast, pirfenidone decreased cell proliferation and matrix synthesis in both fibroblast subpopulations. Pirfenidone slightly attenuated TGF-ß1 induced expression of fibronectin and α-smooth muscle actin in fibroblast cultures, without impairing cell viability. To summarize, manipulation of the TGF-ß signaling pathway by pirfenidone represents a specific antifibrotic approach with no toxic side effects in two human orbital fibroblast subtypes. We presume that pirfenidone is a promising candidate for the treatment of fibrosis following glaucoma surgery.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Proliferação de Células/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Fibroblastos/patologia , Piridonas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Fator de Crescimento Transformador beta/antagonistas & inibidores , Actinas/análise , Actinas/genética , Células Cultivadas , Matriz Extracelular/efeitos dos fármacos , Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Matriz Extracelular/patologia , Fibroblastos/citologia , Fibroblastos/metabolismo , Fibronectinas/análise , Fibronectinas/genética , Fibrose , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Fator de Crescimento Transformador beta/metabolismoRESUMO
PURPOSE: Corneal collagen cross-linking (CXL) is associated with massive cellular damage, the long-term clinical consequences of which have still to be elucidated. In this study, we seek to determine whether matrix-based regenerating agent (RGTA) therapy has a positive influence on stromal regeneration after CXL. METHODS: Twelve New Zealand white rabbits were randomly divided into 2 groups of 6. CXL of the right cornea was performed in both groups, followed by topical corneal application of one drop of vehicle or one drop of RGTA. In vivo confocal laser-scanning microscopy was used to monitor corneal changes over time. At the end of the experiment, 2 weeks postoperatively, the corneas were excised and processed for histology. RESULTS: Epithelial healing was noted in both groups 3 days after CXL. One week after treatment, in vivo confocal laser-scanning microscopy in both groups revealed a significantly thicker acellular stromal zone in the vehicle group compared with the RGTA group (P = 0.0165). This difference persisted up to 2 weeks postoperatively, when acellular zone thickness was 96 ± 10 µm in the RGTA group and 146 ± 34 µm in the vehicle group (P = 0.0058). These findings were confirmed by histology, which also revealed earlier cell repopulation in the RGTA group. CONCLUSIONS: The anterior stroma of cross-linked corneas exhibited cell loss after CXL. Cell repopulation in the anterior corneal stroma occurred earlier when CXL was followed by topical RGTA treatment. Further studies are required to examine the impact of this ophthalmic RGTA on corneal nerve regeneration after CXL.
Assuntos
Colágeno/metabolismo , Substância Própria/metabolismo , Reagentes de Ligações Cruzadas , Glicosaminoglicanos/uso terapêutico , Fármacos Fotossensibilizantes/uso terapêutico , Cicatrização/efeitos dos fármacos , Animais , Córnea/inervação , Ceratócitos da Córnea/fisiologia , Epitélio Corneano/fisiologia , Microscopia Confocal , Fibras Nervosas/patologia , Período Pós-Operatório , Coelhos , Reepitelização , Riboflavina/uso terapêutico , Nervo Trigêmeo/patologia , Raios UltravioletaRESUMO
PURPOSE: Drug-eluting stents (DES) based on permanent polymeric coating matrices have been introduced to overcome the in stent restenosis associated with bare metal stents (BMS). A further step was the development of DES with biodegradable polymeric coatings to address the risk of thrombosis associated with first-generation DES. In this study we evaluate the biocompatibility of biodegradable polymer materials for their potential use as coating matrices for DES or as materials for fully bioabsorbable vascular stents. MATERIALS AND METHODS: Five different polymers, poly(L-lactide) PLLA, poly(D,L-lactide) PDLLA, poly(L-lactide-co-glycolide) P(LLA-co-GA), poly(D,L-lactide-co-glycolide) P(DLLA-co-GA) and poly(L-lactide-co-ε-caprolactone), P(LLA-co-CL) were examined in vitro without and with surface modification. The surface modification of polymers was performed by means of wet-chemical (NaOH and ethylenediamine (EDA)) and plasma-chemical (O2 and NH3) processes. The biocompatibility studies were performed on three different cell types: immortalized mouse fibroblasts (cell line L929), human coronary artery endothelial cells (HCAEC) and human umbilical vein endothelial cells (HUVEC). The biocompatibility was examined quantitatively using in vitro cytotoxicity assay. Cells were investigated immunocytochemically for expression of specific markers, and morphology was visualized using confocal laser scanning (CLSM) and scanning electron (SEM) microscopy. Additionally, polymer surfaces were examined for their thrombogenicity using an established hemocompatibility test. RESULTS: Both endothelial cell types exhibited poor viability and adhesion on all five unmodified polymer surfaces. The biocompatibility of the polymers could be influenced positively by surface modifications. In particular, a reproducible effect was observed for NH3-plasma treatment, which enhanced the cell viability, adhesion and morphology on all five polymeric surfaces. CONCLUSION: Surface modification of polymers can provide a useful approach to enhance their biocompatibility. For clinical application, attempts should be made to stabilize the plasma modification and use it for coupling of biomolecules to accelerate the re-endothelialization of stent surfaces in vivo.
Assuntos
Materiais Biocompatíveis/administração & dosagem , Materiais Biocompatíveis/química , Polímeros/administração & dosagem , Polímeros/química , Propriedades de Superfície/efeitos dos fármacos , Trombose/induzido quimicamente , Animais , Linhagem Celular , Vasos Coronários/efeitos dos fármacos , Stents Farmacológicos/efeitos adversos , Fibroblastos/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Humanos , Camundongos , Stents/efeitos adversosRESUMO
PURPOSE: A novel glaucoma drainage device (GDD) with local drug delivery (LDD) system was created and characterized for safety and effectiveness after implantation into the suprachoroidal space (SCS) of rabbit eyes. METHODS: Thin films of two different polymers, Poly(3-hydroxybutyrate) (P(3HB)) and Poly(4-hydroxybutyrate) (P(4HB)), containing the drugs mitomycin C (MitC) or paclitaxel (PTX) were attached to silicone-tubes to create LDD devices. The release kinetics of these drugs were explored in vitro using high performance liquid chromatography (HPLC). Twenty-four New Zealand white rabbits, randomly divided into eight groups, were implanted with different kinds of microstents into SCS. The intraocular pressure (IOP) was monitored noninvasively. After 6 weeks, rabbits were sacrificed and enucleated eyes were used for anterior segment optical coherence tomography (OCT), micro magnetic resonance imaging (MRI), and histology. RESULTS: In vitro, faster drug release from both polymers was observed for MitC compared to PTX. Comparing polymers, the release from P(3HB) matrix was slower for both drugs. MRI and OCT showed all implants maintained a proper location. An effective IOP reduction was observed for up to 6 weeks in eyes with microstents combined with a drug-releasing LDD system. Overall, the surrounding tissue revealed mild-to-moderate inflammation. No pronounced fibrosis was observed in any of the groups. However, both drugs caused damage to the neighboring retina. CONCLUSIONS: The suprachoroidal microstent reduced IOP with mild inflammation in rabbit eyes. To avoid negative effects on the retina, it is necessary to identify novel drugs with less cytotoxicity. Future studies are needed to explore the fibrotic process over the long-term. TRANSLATIONAL RELEVANCE: The presented data serve as a proof of principle study for the concept of a suprachoroidal drug eluting microstent. Future device improvements will be focused on the design of LDD systems and the use of specific anti-inflammatory or antifibrotic agents with less cytotoxicity compared to MitC or PTX. Long-term animal studies using a reliable glaucoma model will be a further step towards clinical application and improvement of surgical glaucoma therapy.
RESUMO
In this study we present the development of an injectable polymeric drug delivery system for subconjunctival treatment of primary open angle glaucoma. The system consists of hyaluronic acid sodium salt (HA), which is commonly used in ophthalmology in anterior segment surgery, and an isocyanate-functionalized 1,2-ethylene glycol bis(dilactic acid) (ELA-NCO). The polymer mixtures with different ratios of HA to ELA-NCO (1/1, 1/4, and 1/10 (v/v)) were investigated for biocompatibility, degradation behavior and applicability as a sustained release system. For the latter, the lipophilic latanoprost ester pro-drug (LA) was incorporated into the HA/ELA-NCO system. In vitro, a sustained LA release over a period of about 60days was achieved. In cell culture experiments, the HA/ELA-NCO (1/1, (v/v)) system was proven to be biocompatible for human and rabbit Tenon's fibroblasts. Examination of in vitro degradation behavior revealed a total mass loss of more than 60% during the observation period of 26weeks. In vivo, LA was continuously released for 152days into rabbit aqueous humor and serum. Histological investigations revealed a marked leuko-lymphocytic infiltration soon after subconjunctival injection. Thereafter, the initial tissue reaction declined concomitantly with a continuous degradation of the polymer, which was completed after 10months. Our study demonstrates the suitability of the polymer resulting from the reaction of HA with ELA-NCO as an injectable local drug delivery system for glaucoma therapy, combining biocompatibility and biodegradability with prolonged drug release.
Assuntos
Túnica Conjuntiva , Glaucoma de Ângulo Aberto/tratamento farmacológico , Animais , Humor Aquoso/metabolismo , Materiais Biocompatíveis , Células Cultivadas , Preparações de Ação Retardada , Portadores de Fármacos , Sistemas de Liberação de Medicamentos , Olho/patologia , Glaucoma de Ângulo Aberto/patologia , Humanos , Ácido Hialurônico/administração & dosagem , Ácido Hialurônico/uso terapêutico , Injeções , Latanoprosta , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/uso terapêutico , Polímeros , Pró-Fármacos/administração & dosagem , Prostaglandinas F Sintéticas/administração & dosagem , Prostaglandinas F Sintéticas/uso terapêutico , CoelhosRESUMO
Keratocytes are specialized, neural crest-derived mesenchymal cells occupying approximately 3% of the corneal stromal volume. They reside between the collagen lamellae and are responsible for the secretion of extracellular matrix macromolecules, thus contributing to the corneal transparency and integrity. During the regeneration process after infection, traumata and refractive surgery, the keratocytes undergo transition into divergent phenotypes, which are referred to as "activated keratocytes". Quite shortly after injury, the keratocytes lose their quiescence, enter into the cell cycle and migrate toward the site of injury. In certain types of injury, which affect the integrity of basement membrane, activated keratocytes also participate in wound closure by production of α-smooth muscle actin (α-SMA). Since the activated keratocytes are the major cell type contributing to tissue repair during corneal wound healing, their morphological and biochemical properties have been studied in details in experimental studies using light and electron microscopy. More recently, emerging of in vivo microscopy techniques has opened new possibilities to investigate cornea in vivo. The non-invasive nature of this imaging modality enables repeated examination of the same tissue over time and is an ideal tool to rapidly and accurately investigate corneal wound healing. However, the in vivo data on activated keratocytes are not as uniform as data from experimental ex vivo studies. There is still inconsistency in the literature findings on activated phenotypes, and often the described morphologies cannot be appreciated in in vivo images. In this article, a literature review was performed in order to interpret the morphology of different activated phenotypes, based on biological processes underlying the morphological alterations.